AbbVie Inc (ABBV)vsbiote Corp (BTMD)
ABBV
AbbVie Inc
$249.93
+0.85%
HEALTHCARE · Cap: $430.82B
BTMD
biote Corp
$1.54
0.00%
HEALTHCARE · Cap: $80.35M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 34118% more annual revenue ($64.39B vs $188.16M). ABBV leads profitability with a 9.8% profit margin vs 8.3%. BTMD trades at a lower P/E of 5.3x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
BTMD
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-64.0%
Fair Value
$151.19
Current Price
$249.93
$98.74 premium
Margin of Safety
+46.5%
Fair Value
$3.96
Current Price
$1.54
$2.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 8.3%
Earnings declined 83.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : BTMD
The strongest argument for BTMD centers on P/E Ratio, Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : BTMD
The primary concerns for BTMD are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
BTMD carries more volatility with a beta of 1.65 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 35/100) and 10.2% revenue growth. BTMD offers better value entry with a 46.5% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
biote Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
biote corp. The company is headquartered in Irvine, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?